Harmony Biosciences Anticipates Revenue Growth In Q4, FY24; Stock Up

(RTTNews) - Harmony Biosciences Holdings, Inc. (HRMY), Monday announced preliminary net product revenue for the fourth quarter and fiscal year 2024.

For the quarter ending December 31, the biotechnology company estimates net product revenue of approximately $201 million, compared to $168.4 million for the same period in 2023.

Whereas, the net product revenue was expected to be approximately $714 million for the full year 2024, compared to $582 million in prior year.

Analysts, on average, forecast revenue of $198.6 million for the fourth quarter, and $712.05 million for the fiscal year 2024.

Looking ahead, Harmony sees net revenue of $820 million to $860 million for fiscal year 2025.

Currently, Harmony's stock is climbing 9.18 percent, to $36.97 on the Nasdaq.